Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 July 2016Next earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
APVO Latest News
Aptevo Therapeutics (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update. "After the successful completion of our APVO436 dose expansion trial, where we saw a 91% clinical benefit rate and an excellent safety, tolerability and duration of remission profile, we worked in the second quarter to finalize plans for the launch of the first part of our Phase 1b/2 trial, a dose optimization study, continuing evaluation of APVO436 in combination with venetoclax and azacitidine for the treatment of Acute Myeloid Leukemia (AML) in frontline patients.
SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.
Aptevo's stock drops following the issuance of additional shares at a discounted price, resulting in a significant dilution of existing shareholders.
Aptevo Therapeutics (NASDAQ: APVO) shares are declining today following the announcement of a public offering in which the company will sell 3.4 million shares of APVO stock at $1.35 per share.
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company will present at the upcoming Bio-Europe conference occurring November 6-8, 2023 in Munich, Germany. Details of the Company's presentation, which will highlight its pipeline of clinical and pre-clinical bispecific drug candidates designed to fight both solid and hematologic malignancies, are as follows: Date & Time: Tuesday, November 7, 2023 @ 1:15 CET (8:15 Eastern time) Location: Trade Fair Center Messe München, San Sabastian Room, Munich, Germany Presenter: Michelle Nelson, Ph.D.
Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poor.
What type of business is Aptevo Therapeutics?
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
What sector is Aptevo Therapeutics in?
Aptevo Therapeutics is in the Healthcare sector
What industry is Aptevo Therapeutics in?
Aptevo Therapeutics is in the Biotechnology industry
What country is Aptevo Therapeutics from?
Aptevo Therapeutics is headquartered in United States
When did Aptevo Therapeutics go public?
Aptevo Therapeutics initial public offering (IPO) was on 20 July 2016
What is Aptevo Therapeutics website?
https://www.aptevotherapeutics.com
Is Aptevo Therapeutics in the S&P 500?
No, Aptevo Therapeutics is not included in the S&P 500 index
Is Aptevo Therapeutics in the NASDAQ 100?
No, Aptevo Therapeutics is not included in the NASDAQ 100 index
Is Aptevo Therapeutics in the Dow Jones?
No, Aptevo Therapeutics is not included in the Dow Jones index
When was Aptevo Therapeutics the previous earnings report?
No data
When does Aptevo Therapeutics earnings report?
The next expected earnings date for Aptevo Therapeutics is 14 November 2024